Pathogenesis of airway inflammation in bronchial asthma

Auris Nasus Larynx

Volumn 38, Issue 5, 2011, Pages 555-563

  Nakagome, Kazuyuki ^a   Nagata, Makoto ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bronchial asthma; Cysteinyl leukotrienes; Eosinophils; IL 5; Mast cells; Neutrophils

Indexed keywords

ALLERGEN; AMPHIREGULIN; BETA CHEMOKINE; CORTICOSTEROID; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 8; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PEPTIDOLEUKOTRIENE; PREDNISONE; VASCULAR CELL ADHESION MOLECULE 1;

AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; BRONCHUS HYPERREACTIVITY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; CELL MIGRATION; DEGRANULATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EOSINOPHIL; EOSINOPHILIA; HUMAN; IMMUNOTHERAPY; LEUKOCYTE ACTIVATION; MAST CELL; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN SECRETION; RESPIRATORY TRACT INFLAMMATION; REVIEW; TH1 CELL; TH2 CELL;

ASTHMA; BRONCHITIS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EOSINOPHILIA; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-5; LEUKOTRIENES; MAST CELLS; NEUTROPHILS; RHINITIS; SEVERITY OF ILLNESS INDEX;

EID: 79954583352     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2011.01.011     Document Type: Review

References (100)

1. Bochner B.S., Undem B.J., Lichtenstein L.M. Immunological aspects of allergic asthma. Annu Rev Immunol 1994, 12:295-335.
2. Gleich G.J. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000, 105:651-663.
3. Weller P.F. Human eosinophils. J Allergy Clin Immunol 2000, 100:283-287.
4. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
5. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167:1655-1659.
6. Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-1071.
7. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167:199-204.
8. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
9. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
10. Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004, 103:2939-2941.
11. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004, 113:115-119.
12. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215-1228.
13. Flood-Page P.T., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112:1029-1036.
14. Humbles A.A., Lloyd C.M., McMillan S.J., Friend D.S., Xanthou G., McKenna E.E., et al. A critical role for eosinophils in allergic airways remodeling. Science 2004, 305:1776-1779.
15. Lee J.J., Dimina D., Macias M.P., Ochkur S.I., Mcgarry M.P., O'Neill K.R., et al. Definng a link with asthma in mice congenitally deficient in eosinophils. Science 2004, 305:1773-1776.
16. Sedgwick J.B., Nagata M. Mechanism of eosinophil activation. Asthma and rhinitis 2000, 373-393. Blackwell Scientific, Boston. W.W. Busse, S.T. Holgate (Eds.).
17. Seymour M.L., Rak S., Aberg D., Riise G.C., Penrose J.F., Kanaoka Y., et al. Leukotriene and prostanoid pathway enzymes in bronchial biopsies of seasonal allergic asthmatics. Am J Resp Crit Care Med 2001, 164:2051-2056.
18. Cowburn A.S., Sladek K., Soja J., Adamek L., Nizankowska E., Szczeklik A., et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998, 101:834-846.
19. Bochner B.S. Cellular adhesion its antagonism. J Allergy Clin Immunol 1997, 100:581-585.
20. Schleimer R.P., Sterbinsky S.A., Kaiser J., Bickel C.A., Klunk D.A., Tomioka K., et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 1992, 148:1086-1092.
21. Bochner B.S., Klunk D.A., Sterbinsky S.A., Coffman R.L., Schleimer R.P. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995, 154:799-803.
22. Nagata M., Sedgwick J.B., Kita H., Busse W.W. Granulocyte macrophage colony-stimulating factor augments ICAM-1 and VCAM-1 activation of eosinophil function. Am J Respir Cell Mol Biol 1998, 19:158-166.
23. Nagata M., Sedgwick J.B., Bates M.E., Kita H., Busse W.W. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. J Immunol 1995, 155:2194-2202.
24. Nagata M., Sedgwick J.B., Vrtis R., Busse W.W. Endothelial cells upregulate eosinophil superoxide generation via VCAM-1 expression. Clin Exp Allergy 1999, 29:550-561.
25. Nagata M., Yamamoto H., Tabe K., Sakamoto Y. Eosinophil transmigration across VCAM-1-expressing endothelial cells is upregulated by antigen-stimulated mononuclear cells. Int Arch Allergy Immunol 2001, 125(S1):7-11.
26. Sabatini F., Silvestri M., Sale R., Scarso L., Defilippi A.C., Risso F.M., et al. Fibroblast-eosinophil interaction: modulation of adhesion molecules expression and chemokine release by human fetal lung fibroblasts in response to IL-4 and TNF-alpha. Immunol Lett 2002, 84:173-178.
27. Atasoy U., Curry S.L., Lopez de Silanes I., Shyu A.B., Casolaro V., Gorospe M., et al. Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA stabilization: involvement of the RNA-binding protein HuR. J Immunol 2003, 171:4369-4378.
28. Fujisawa T., Kato Y., Atsuta J., Terada A., Iguchi K., Kamiya H., et al. Chemokine production by the BEAS-2B human bronchial epithelial cells: differential regulation of eotaxin, IL-8, and RANTES by TH2- and TH1-derived cytokines. J Allergy Clin Immunol 2000, 105:126-133.
29. Liu L.Y., Sedgwick J.B., Bates M.E., Vrtis R.F., Gern J.E., Kita H., et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002, 169:6459-6466.
30. Liu L.Y., Sedgwick J.B., Bates M.E., Vrtis R.F., Gern J.E., Kita H., et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002, 169:6452-6458.
31. Atsuta J., Plitt J., Bochner B.S., Schleimer R.P. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am J Respir Cell Mol Biol 1999, 20:643-650.
32. Wilson S.J., Wallin A., Della-Cioppa G., Sandström T., Holgate S.T. Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001, 164:1047-1052.
33. Laitinen L.A., Laitinen A., Haahtela T., Vilkka V., Spur B.W., Lee T.H. Leukotriene E4 and granulocytes infiltration into asthmatic airways. Lancet 1993, 341:989-990.
34. Nagata M., Saito K., Tsuchiya T., Sakamoto Y. Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol 2002, 109:676-770.
35. Saito K., Nagata M., Kikuchi I., Sakamoto Y. Leukotriene D4 and eosinophil transendothelial migration, superoxide generation, and degranulation via beta2 integrin. Ann Allergy Asthma Immunol 2004, 93:594-600.
36. Currie G.P., Lee D.K., Haggart K., Bates C.E., Lipworth B.J. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003, 167:1232-1238.
37. Bjermer L., Bisgaard H., Bousquet J., Fabbri L.M., Greening A.P., Haahtela T., et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003, 327:891-896.
38. Kushiya M., Saito K., Kikuchi I., Kobayashi T., Hagiwara K., Kanazawa M., et al. Differential effects of salbutamol and montelukast on eosinophil adhesion and superoxide anion generation. Int Arch Allergy Immunol 2006, 140(Suppl. 1):17-22.
39. Larche M., Robinson D.S., Kay A.B. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003, 111:450-463.
40. Humbert M., Corrigan C.J., Kimmitt P., Till S.J., Kay A.B., Durham S.R. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997, 156:704-708.
41. Humbert M., Menz G., Ying S., Corrigan C.J., Robinson D.S., Durham S.R., et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999, 20:528-533.
42. Hogan S.P., Matthaei K.I., Young J.M., Koskinen A., Young I.G., Foster P.S. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol 1998, 161:1501-1509.
43. Gavett S.H., Chen X., Finkelman F., Wills-Karp M. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol 1994, 10:587-593.
44. Cohn L., Tepper J.S., Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol 1998, 161:3813-3816.
45. Hansen G., Berry G., DeKruyff R.H., Umetsu D.T. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999, 103:175-183.
46. Shannon J., Ernst P., Yamauchi Y., Olivenstein R., Lemiere C., Foley S., et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008, 133:420-426.
47. Randolph D.A., Stephens R., Carruthers C.J., Chaplin D.D. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest 1999, 104:1021-1029.
48. Randolph D.A., Carruthers C.J., Szabo S.J., Murphy K.M., Chaplin D.D. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J Immunol 1999, 162:2375-2383.
49. Sugimoto T., Ishikawa Y., Yoshimoto T., Hayashi N., Fujimoto J., Nakanishi K. Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J Exp Med 2004, 199:535-545.
50. Stephens R., Randolph D.A., Huang G., Holtzman M.J., Chaplin D.D. Antigen-nonspecific recruitment of Th2 cells to the lung as a mechanism for viral infection-induced allergic asthma. J Immunol 2002, 169:5458-5467.
51. Kobayashi T., Takaku Y., Yokote A., Miyazawa H., Soma T., Hagiwara K., et al. Interferon-beta augments eosinophil adhesion-inducing activity of endothelial cells. Eur Respir J 2008, 32:1540-1547.
52. Belosevic M., Finbloom D.S., Van Der Meide P.H., Slayter M.V., Nacy C.A. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 1989, 143:266-274.
53. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
54. Reinhardt R.L., Khoruts A., Merica R., Zell T., Jenkins M.K. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001, 410:101-105.
55. Ahmadzadeh M., Hussain S.F., Farber D.L. Heterogeneity of the memory CD4 T cell response: persisting effectors and resting memory T cells. J Immunol 2001, 166:926-935.
56. Wise J.T., Baginski T.J., Mobley J.L. An adoptive transfer model of allergic lung inflammation in mice is mediated by CD4+CD62LlowCD25+ T cells. J Immunol 1999, 162:5592-5600.
57. Nakagome K., Dohi M., Okunishi K., To Y., Sato A., Komagata Y., et al. Antigen-sensitized CD4+CD62Llow memory/effector T helper 2 cells can induce airway hyperresponsiveness in an antigen free setting. Respir Res 2005, 6:46.
58. Brightling C.E., Bradding P., Symon F.A., Holgate S.T., Wardlaw A.J., Pavord I.D. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-1705.
59. Brightling C.E., Ammit A.J., Kaur D., Black J.L., Wardlaw A.J., Hughes J.M., et al. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med 2005, 171:1103-1108.
60. Okumura S., Sagara H., Fukuda T., Saito H., Okayama Y. Fc epsilon RI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells. J Allergy Clin Immunol 2005, 115:272-279.
61. Bousquet J., Cabrera P., Berkman N., Buhl R., Holgate S., Wenzel S., et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-308.
62. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
63. Wenzel S.E., Schwartz L.B., Langmack E.L., Halliday J.L., Trudeau J.B., Gibbs R.L., et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999, 160:1001-1008.
64. The ENFUMOSA Study Group The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003, 22:470-477.
65. Kikuchi S., Nagata M., Kikuchi I., Hagiwara K., Kanazawa M. Association between neutrophilic and eosinophilic inflammation in patients with severe persistent asthma. Int Arch Allergy Immunol 2005, 137(S1):7-11.
66. Pepe C., Foley S., Shannon J., Lemiere C., Olivenstein R., Ernst P., et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005, 116:544-549.
67. Kikuchi S., Kikuchi I., Takaku Y., Kobayashi T., Hagiwara K., Kanazawa M., et al. Neutrophilic inflammation and CXC chemokines in patients with refractory asthma. Int Arch Allergy Immunol 2009, 149(S1):87-93.
68. Kikuchi I., Kikuchi S., Kobayashi T., Hagiwara K., Sakamoto Y., Kanazawa M., et al. Eosinophil trans-basement membrane migration induced by interleukin-8 and neutrophils. Am J Respir Cell Mol Biol 2006, 34:760-765.
69. Goleva E., Hauk P.J., Hall C.F., Liu A.H., Riches D.W., Martin R.J., et al. Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. J Allergy Clin Immunol 2008, 122:550-559.
70. Zhu Z., Zheng T., Homer R.J., Kim Y.K., Chen N.Y., Cohn L., et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004, 304:1678-1682.
71. Hong J.H., Hong J.Y., Park B., Lee S.I., Seo J.T., Kim K.E., et al. Chitinase activates protease-activated receptor-2 in human airway epithelial cells. Am J Respir Cell Mol Biol 2008, 39:530-535.
72. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852.
73. Barczyk A., Pierzchala W., Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 2003, 97:726-733.
74. Al-Ramli W., Préfontaine D., Chouiali F., Martin J.G., Olivenstein R., Lemière C., et al. TH17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009, 123:1185-1187.
75. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
76. Murphy K.M., Ouyang W., Farrar J.D., Yang J., Ranganath S., Asnagli H., et al. Signaling and transcription in T helper development. Annu Rev Immunol 2000, 18:451-460.
77. Möller G.M., Overbeek S.E., Van Helden-Meeuwsen C.G., Van Haarst J.M., Prens E.P., Mulder P.G., et al. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulation by inhaled corticosteroids. Clin Exp Allergy 1996, 26:517-524.
78. Tunon-De-Lara J.M., Redington A.E., Bradding P., Church M.K., Hartley J.A., Semper A.E., et al. Dendritic cells in normal and asthmatic airways: expression of the alpha subunit of the high affinity immunoglobulin E receptor (Fc epsilon RI-alpha). Clin Exp Allergy 1996, 26:648-655.
79. Lambrecht B.N., De Veerman M., Coyle A.J., Gutierrez-Ramos J.C., Thielemans K., Pauwels R.A. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000, 106:551-559.
80. Nakagome K., Dohi M., Okunishi K., Komagata Y., Nagatani K., Tanaka R., et al. In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation. J Immunol 2005, 174:6955-6966.
81. Lambrecht B.N., Hammad H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 2003, 3:994-1003.
82. van Rijt L.S., Jung S., Kleinjan A., Vos N., Willart M., Duez C., et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 2005, 201:981-991.
83. Drachenberg K.J., Wheeler A.W., Stuebner P., Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56:498-505.
84. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002, 168:926-932.
85. Nakagome K., Okunishi K., Imamura M., Harada H., Matsumoto T., Tanaka R., et al. IFN-γ attenuates antigen-induced overall immune response in the airway as a Th1-type immune regulatory cytokine. J Immunol 2009, 183:209-220.
86. Leynaert B., Neukirch F., Demoly P., Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000, 106:S201-S205.
87. Djukanović R., Lai C.K., Wilson J.W., Britten K.M., Wilson S.J., Roche W.R., et al. Bronchial mucosal manifestations of atopy: a comparison of markers of inflammation between atopic asthmatics, atopic nonasthmatics and healthy controls. Eur Respir J 1992, 5:538-544.
88. Corren J., Adinoff A.D., Irvin C.G. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992, 89:611-618.
89. Gaga M., Lambrou P., Papageorgiou N., Koulouris N.G., Kosmas E., Fragakis S., et al. Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy 2000, 30:663-669.
90. Braunstahl G.J., Kleinjan A., Overbeek S.E., Prins J.B., Hoogsteden H.C., Fokkens W.J. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000, 161:2051-2057.
91. Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A., et al. World Health Organization; GA2LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008, 63(Suppl. 86):8-160.
92. Welsh P.W., Stricker W.E., Chu C.P., Naessens J.M., Reese M.E., Reed C.E., et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987, 62:125-134.
93. Henriksen J.M., Wenzel A. Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma. Am Rev Respir Dis 1984, 130:1014-1018.
94. Foresi A., Pelucchi A., Gherson G., Mastropasqua B., Chiapparino A., Testi R. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996, 98:274-282.
95. Corren J., Adinoff A.D., Buchmeier A.D., Irvin C.G. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992, 90:250-256.
96. Nakada H., Nakagome K., Takaku Y., Nishihara F., Yamaguchi T., Soma T., et al. Questionnaire for determining relationship between nasal and asthma symptoms. Arerugi 2010, 59:688-698. [in Japanese].
97. Price D.B., Swern A., Tozzi C.A., Philip G., Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006, 61:737-742.
98. Abramson M.J., Puy R.M., Weiner J.M. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995, 151:969-974.
99. Möller C., Dreborg S., Ferdousi H.A., Halken S., Høst A., Jacobsen L., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256.
100. Nagakura T., Ogino S., Okubo K., Sato N., Takahashi M., Ishikawa T. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy 2007, 38:329-337.